Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Jul;16(7):927-930.
doi: 10.1513/AnnalsATS.201810-720RL.

Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation

Toby M Maher  1   2 , Lisa H Lancaster  3 , Stéphane Jouneau  4   5 , Lake Morrison  6 , David J Lederer  7 , Maria Molina-Molina  8   9 , Elisabeth Bendstrup  10 , Klaus-Uwe Kirchgaessler  11 , Frank Gilberg  11 , Judit Axmann  11 , Ute Petzinger  12 , Paul W Noble  13
Affiliations
Randomized Controlled Trial

Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation

Toby M Maher et al. Ann Am Thorac Soc. 2019 Jul.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Treatment periods for calculating annual forced vital capacity (FVC) decline during CAPACITY and RECAP to assess the association of FVC decline and timing of pirfenidone initiation (aim 2). *Pirfenidone was titrated from 801 mg/d over the first 15 days in RECAP up to the maintenance dose (or maximum tolerated dose if this was lower). CAPACITY = Clinical Studies Assessing Pirfenidone in Idiopathic Pulmonary Fibrosis: Research of Efficacy and Safety Outcomes.
Figure 2.
Figure 2.
Rate of lung function decline over 180 weeks by baseline % predicted forced vital capacity (FVC) category in RECAP.
Figure 3.
Figure 3.
Annual rate of lung function decline in CAPACITY and RECAP by treatment group during CAPACITY. *Annual rates of forced vital capacity (FVC) decline during RECAP were calculated on the basis of all available RECAP FVC values, but only presented up to Week 220. CAPACITY = Clinical Studies Assessing Pirfenidone in Idiopathic Pulmonary Fibrosis: Research of Efficacy and Safety Outcomes. Adapted by permission from Reference .
See this image and copyright information in PMC

References

    1. Ley B, Collard HR, King TE., Jr Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431–440. - PubMed
    1. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of idiopathic pulmonary fibrosis: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44–e68. - PubMed
    1. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760–1769. - PubMed
    1. King TE, Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–2092. - PubMed
    1. Albera C, Costabel U, Fagan EA, Glassberg MK, Gorina E, Lancaster L, et al. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J. 2016;48:843–851. - PubMed

Publication types

MeSH terms

Associated data